logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11518805 B1

PDFFull Text
Date of Patent:
Dec. 06, 2022

Filed:

Apr. 30, 2020

Binding inhibitor between tctp dimer type ige-dependent histamine releasing factor and receptor thereof, and use thereof

Applicant:

Ewha University—industry Collaboration Foundation, Seoul, KR;

Inventor:

Kyunglim Lee, Seoul, KR;

Assignee:

EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION, Seoul, KR;

Attorney:

Klarquist Sparkman, LLP

Primary Examiner:

Michael Szperka

Int. Cl.
CPC ...
C07K 7/00 (2006.01); C07K 16/24 (2006.01); A61K 38/16 (2006.01); A61K 39/395 (2006.01); C07K 14/47 (2006.01); A61K 38/19 (2006.01); A61P 27/14 (2006.01); C07K 14/52 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/244 (2013.01); A61K 9/14 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 38/16 (2013.01); A61K 38/19 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61P 27/14 (2018.01); C07K 14/4703 (2013.01); C07K 14/52 (2013.01); A61K 2039/505 (2013.01); C07K 2317/35 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structural region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, rhinitis, atopic dermatitis, and anaphylaxis; inflammatory diseases such as rheumatoid arthritis; and malaria, and a method for screening for the HRF-related diseases.

Find Patent Forward Citations

Loading…